Since late June, the *2019 Journal Citation Report* by Clarivate analytics is out. The *European Journal of Vascular and Endovascular Surgery* (EJVES) has reached, for the first time ever, a Journal Impact Factor (JIF) above 5: **the EJVES 2019 JIF is 5.328**. This means, on average, that each EJVES paper published in 2017 or 2018 was cited more than 5 times in 2019. This represents a stunning increase by 46% compared with the 2018 JIF and has the EJVES now ranking 8 out of 210 surgical specialty journals (2018: 28 out of 203).[@bib1] By comparison, the *Journal of Vascular Surgery* (JVS) reached a 2019 JIF of 3.405 (up 5% from 2018) and ranks 37, while the *Journal of Endovascular Therapy* (JEVT) has a JIF of 3.102 (up 4%) and ranks 46. Therefore, after taking a dip over the past two years, the EJVES is on the rise again and remains, for the fourth year in a row, the leading vascular surgery journal.

Many factors have contributed to this success: the development of improved reporting standards and an unique Journal style of presentation,[@bib2] ^,^ [@bib3] the diversification into specialized companion Journals,[@bib4] the increased activity on social media platforms,[@bib2] ^,^ [@bib5] and the professionalization of editorial workflows,[@bib3] all of which have led to an ever increasing interest and quality of submitted papers to be selected through a reliable peer review process by dedicated experts in the field. Indeed, on average each accepted full length article has undergone scrutiny by 3.7 reviewers, completing a mean of 8 reviews. These quota have been stable over the past few years and represent the backbone of the EJVES quality assurance programme. In addition, we have introduced a four-eye editorial decision making principle for the main sections in 2020.[@bib3]

The Journal\'s success has been accompanied by a steady rise of submissions: from 847 in 2016 to 1206 in 2019 and probably to around 1600 in 2020. This, in turn, must lead to increased rejection rates, if the Journal does not want to outgrow its size.[@bib3] Currently, the rejection rate for full length articles ranges around 80%. As a service to our submitting authors, we have increased the desktop rejection rate which has already reached 50% of all rejections. Thereby, submitted articles are screened first by the handling editor. If the submission does not meet minimum standards, it is rejected immediately in order to avoid unnecessary delays and efforts for everybody involved.[@bib3]

Out of the 10 papers that contributed most citations to the 2019 EJVES JIF, five were **European Society for Vascular Surgery (ESVS) clinical practice guidelines**: The ESVS management guidelines for carotid disease[@bib6] contributed the highest number of citations, followed by the conjoint *European Society of Cardiology* (ESC)/ESVS management guidelines for peripheral arterial disease;[@bib7] the ESVS guidelines on descending thoracic aortic diseases;[@bib8] on vascular access;[@bib9] and on diseases of the mesenteric arteries and veins.[@bib10] The updated guidelines on abdominal aortic aneurysm[@bib11] and chronic limb threatening ischaemia (the first global vascular guidelines developed conjointly by the ESVS, the *Society for Vascular Surgery* (SVS) and the *World Federation of Vascular Societies* (WFVS))[@bib12] were published in 2019 and will contribute to the 2020 JIF. All these guidelines represent one of the **core missions of the ESVS**, to deliver continued medical education to our fellow vascular specialists and best possible care to all our patients.

The JIF is not the only way to evaluate the clinical and scientific importance of a journal. The measure is arbitrary, and actually more adopted to basic than to clinical research. Still, there is a consensus that there is no better proxy to evaluate the scientific importance of a journal. The fact that a paper has been cited, reflects that is has not only been read, but also found to be of such importance that it is included among the key references in subsequent publications. Furthermore, many institutions use this metric as the base for distributing research funding. Thus, many authors who published papers in the EJVES will be rewarded with greater funding in the coming years: Congratulations and many thanks for submitting your high quality research to the EJVES!

Although the high JIF is a gem to treasure, we will continue to publish educational articles, editorials and letters in the EJVES, all of which do not contribute to the JIF. Indeed, we do encourage debates and invite our readers to write letters on controversial hot topics. We recently introduced the *Research Letters*, ideal for short scientific communication of preliminary results or for abbreviated communications about rare disorders or new techniques. For original research articles however, the EJVES has become increasingly competitive for above reasons. Unfortunately, many excellent submissions have to be rejected by the EJVES, but might find an excellent platform on the *EJVES Vascular Forum,* [@bib4] our online companion journal that is Pubmed indexed and expected to receive an JIF of its own very soon.[@bib5] *EJVES Vascular Forum* is open access and interacts closely with social media to promote all scientific ESVS activities.[@bib5] Thus, the ESVS and its journals offer excellent opportunities for everyone to share research findings, critical thoughts and clinical experience, and to engage in interactive discussions and debates.

While many countries have closed their borders during the Covid-19 pandemic, science has maintained its ethical standards. Important data to fight the pandemic was published fast track and shared without restriction. The ESVS and the EJVES are European, but we embrace globalisation. A growing proportion of the journal\'s readers, authors, reviewers, editorial board members, and editors are non-European. This is not by coincidence, but part of a strategy. Working together across borders, increasing diversity, and promoting science, are crucial components of this strategy, in the interest of our patients worldwide. An important part of this success is the linked membership with the ESVS that the vascular societies of India, Lebanon, South Africa, and Australia/New Zeeland offer their members, including subscriptions to the EJVES.

We will not be hosting our 34th Annual Meeting in Krakow this year. Instead, our Annual Meeting becomes the **ESVS month** (September 29th to October 22nd), which will showcase a selection of our scientific and educational programme in an online format. There will be a series of live sessions and workshops run over the course of four weeks, in addition to short abstract sessions early September to select the best abstracts for the main programme. We believe this will be an exciting and interactive alternative to the onsite event.

In practical terms, **LIVE webinars** and **interactive educational sessions** will take place every Tuesday and Thursday. They were designed by the Scientific and Academy Programme Committees to address various key topics in the field of vascular surgery, and will allow direct interaction with the audience. The nine scientific webinars will include **symposia sessions** chaired and delivered by world-renowned experts, as well as **scientific sessions** presenting the best submitted abstracts. In addition, 20 **workshops** will be run by leading international specialists delivering interactive and engaging content to a limited audience. **E-poster presentations** will be available on-demand only, and **Industry-sponsored sessions** will be scheduled before or after scientific webinars and workshops.

All the registered participants will be able to access the sessions LIVE or on-demand during and after the event. We look forward to bring together our community in this new digital format to learn, connect, and interact!

In the midst of the Covid-19 pandemic the ESVS and the EJVES stand strong. We need science and international collaboration more than ever in this era of uncertainty. Every crisis creates opportunities, and in this crisis one such opportunity is to explore new ways to ensure a continued focus on the core values of our profession and personal lives. Take care of yourself, your families and your patients.
